| PRMT5 Inhibition Modulates E2F1 Methylation and Gene-Regulatory Networks Leading to Therapeutic Efficacy in JAK2V617F-Mutant MPN F Pastore, N Bhagwat, A Pastore, A Radzisheuskaya, A Karzai, ... Cancer discovery 10 (11), 1742-1757, 2020 | 61 | 2020 |
| Phase 2 study of ruxolitinib and decitabine in patients with myeloproliferative neoplasm in accelerated and blast phase JO Mascarenhas, RK Rampal, HE Kosiorek, R Bhave, E Hexner, ... Blood advances 4 (20), 5246-5256, 2020 | 56 | 2020 |
| CXCL8/CXCR2 signaling mediates bone marrow fibrosis and is a therapeutic target in myelofibrosis AJ Dunbar, D Kim, M Lu, M Farina, RL Bowman, JL Yang, Y Park, ... Blood, The Journal of the American Society of Hematology 141 (20), 2508-2519, 2023 | 26 | 2023 |
| BMP2/SMAD pathway activation in JAK2/p53-mutant megakaryocyte/erythroid progenitors promotes leukemic transformation B Li, W An, H Wang, T Baslan, S Mowla, A Krishnan, W Xiao, RP Koche, ... Blood, The Journal of the American Society of Hematology 139 (25), 3630-3646, 2022 | 15 | 2022 |
| Therapeutic efficacy of combined JAK1/2, Pan-PIM, and CDK4/6 inhibition in myeloproliferative neoplasms RK Rampal, M Pinzon-Ortiz, AVH Somasundara, B Durham, R Koche, ... Clinical Cancer Research 27 (12), 3456-3468, 2021 | 14 | 2021 |
| KDM6B protects T-ALL cells from NOTCH1-induced oncogenic stress N Issa, H Bjeije, ER Wilson, A Krishnan, WMB Dunuwille, TM Parsons, ... Leukemia 37 (4), 728-740, 2023 | 7 | 2023 |
| Evaluation of tagraxofusp (SL-401) alone and in combination with ruxolitinib for the treatment of myeloproliferative neoplasms A Krishnan, M Pagane, M Roshal, E McGovern, Z Stone-Molloy, J Chen, ... Blood 134, 2967, 2019 | 7 | 2019 |
| PRMT5 inhibition modulates E2F1 methylation and gene-regulatory networks leading to therapeutic efficacy in JAK2V617F-mutant MPN. Cancer Discov 10: 1742–1757 F Pastore, N Bhagwat, A Pastore, A Radzisheuskaya, A Karzai, ... CD-20-0026, 2020 | 6 | 2020 |
| PRMT5 inhibition modulates E2F1 methylation and gene regulatory networks leading to therapeutic efficacy in JAK2VF mutant MPN F Pastore, N Bhagwat, A Krishnan, A Pastore, B Li, RL Bowman, W Xiao, ... Blood 134, 473, 2019 | 5 | 2019 |
| Evaluation of combination tagraxofusp (SL-401) and hypomethylating agent (HMA) therapy for the treatment of chronic myelomonocytic leukemia (CMML) A Krishnan, B Li, M Pagane, E McGovern, Z Stone-Molloy, J Chen, ... Blood 132, 1809, 2018 | 5 | 2018 |
| EPAC regulates melanoma growth by stimulating mTORC1 signaling and loss of EPAC signaling dependence correlates with melanoma progression A Krishnan, AI Bhasker, MK Singh, CI Rodriguez, EC Pérez, S Altameemi, ... Molecular Cancer Research 20 (10), 1548-1560, 2022 | 4 | 2022 |
| LSD1 inhibitor CPI-482 shows efficacy and prolongs survival in mouse models of AML and post-MPN AML in the context of constitutive JAK-STAT pathway activation RK Rampal, JP McGrath, A Krishnan, B Li, W Xiao, D Nikom, J Wang, ... Blood 136, 50-51, 2020 | 3 | 2020 |
| Increased Interleukin-8 (IL8)-CXCR2 Signaling Promotes Progression of Bone Marrow Fibrosis in Myeloproliferative Neoplasms A Dunbar, M Lu, M Farina, Y Park, J Yang, D Kim, A Karzai, ME Salama, ... Blood 136, 6-7, 2020 | 3 | 2020 |
| The BMP/SMAD pathway is a key mediator of leukemic transformation of TP53-Mutant Post-MPN AML B Li, W An, H Wang, A Krishnan, S Mowla, T Baslan, R Koche, W Xiao, ... Blood 138, 626, 2021 | 2 | 2021 |
| JAK2S523L, a novel gain-of-function mutation in a critical autoregulatory residue in JAK2V617F− MPNs F Pastore, A Krishnan, HM Hammarén, O Silvennoinen, B Yan, RL Levine Blood advances 4 (18), 4554-4559, 2020 | 2 | 2020 |
| Modeling clonal evolution and oncogenic dependency in vivo in the context of hematopoietic transformation RL Bowman, A Dunbar, T Mishra, W Xiao, MR Waarts, IF Maestre, ... bioRxiv, 2022.05. 18.492524, 2022 | 1 | 2022 |
| BIRC5 Upregulation Enhances DNMT3A-Mutant T-ALL Cell Survival and Pathogenesis WMB Dunuwille, WC Wilson, H Bjeije, N Issa, W Han, TM Parsons, ... Blood Neoplasia, 100040, 2024 | | 2024 |
| Abstract SY34-02: Age-related and organ-specific host mosaicism as a driver of dormant cancer cell awakening JA Aguirre-Ghiso, M Papanicolaou, PS Vela, J Yang, A Safonov, J Tao, ... Cancer Research 84 (7_Supplement), SY34-02-SY34-02, 2024 | | 2024 |
| Engineering a humanized animal model of polycythemia vera with minimal JAK2V617F mutant allelic burden TM Parsons, A Krishnan, WMB Dunuwille, AL Young, J Arand, W Han, ... Haematologica 109 (3), 968, 2024 | | 2024 |
| 3056–DNMT3A MUTATIONS UPREGULATE CELL ADHESION MOLECULES TO PROMOTE INVASIVENESS OF T-ALL CELLS S Dunuwille, A Krishnan, IX Raj, A Young, G Challen Experimental Hematology 124, S78, 2023 | | 2023 |
